Clinical trial
Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating…
NCT00276809 · German CLL Study Group, Other · Completed
Key facts
| NCT number | NCT00276809 |
|---|---|
| Title | Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia |
| Official title | Campath 1H (Alemtuzumab) Combined With High-Dose Therapy and Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia |
| Lead sponsor | German CLL Study Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | alemtuzumab, filgrastim, carmustine, cyclophosphamide, cytarabine, dexamethasone, etoposide, fludarabine phosphate, melphalan, autologous bone marrow transplantation and 2 more |
| Enrollment | 30 |
| Start date | Jun 1, 2001 |
| Primary completion | Sep 1, 2004 |
| Completion | Sep 1, 2004 |
| First posted | Jan 13, 2006 |
| Last update posted | Sep 26, 2016 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: